The Use of Non–Vitamin K Antagonist Oral Anticoagulants in Post-Kidney Transplantation, Single-Center Experience

Zaitoun, Mohammad F; Sheikh, Mahmoud El; Faifi, Abdullah S Al; Mahedy, Ahmed; Nazer, Weam El; Hennawy, Hany M El

doi:10.1016/j.transproceed.2021.09.042

Cited by 3 publications

(4 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Calcineurin inhibitor levels and estimated glomerular filtration rate did not change significantly in the NOAC group (p = 0.34 and 0.96, respectively). The study showed that, compared to warfarin, NOACs are well-tolerated and effective for preventing and treating thromboembolic events in KTRs [49]. Those results are however of limited significance due to a small study population.…”

Section: Safetymentioning

confidence: 97%

Safety of Non-Vitamin K Antagonist Oral Anticoagulant Treatment in Patients with Chronic Kidney Disease and Kidney Transplant Recipients

et al. 2022

View full text Add to dashboard Cite

The use of novel oral anticoagulants in patients with impaired renal function or undergoing immunosuppressive therapy is limited due to the risk of drug-to-drug interactions and anticoagulation-related adverse events. This article aims to assess the current data on the safety of direct-acting oral anticoagulant-based therapy in the population of kidney transplant recipients and patients with impaired renal function. The most important factors affecting the safety of treatment are the incidence of bleeding events, thromboembolic events, deaths and drug-to-drug interactions. The available data were compared to the findings on warfarin-based anticoagulation. Findings on the use of novel oral anticoagulants in kidney transplant recipients are limited yet promising in terms of safety and efficacy of use. However, current recommendations state that the co-administration of non-vitamin K antagonist oral anticoagulants with several immunosuppressive agents is contraindicated.

show abstract

Section: Safetymentioning

confidence: 97%

Safety of Non-Vitamin K Antagonist Oral Anticoagulant Treatment in Patients with Chronic Kidney Disease and Kidney Transplant Recipients

et al. 2022

View full text Add to dashboard Cite

show abstract

“…In a recent retrospective, single-center analysis by Zaitoun et al, 85 8 renal transplant recipients maintained on a DOAC were compared with matched patients receiving warfarin (n = 8). There were no thromboembolic events or bleeding events in patients treated with a DOAC, whereas there were no thromboembolic events but 3 episodes of bleeding in the warfarin-treated patients.…”

Section: Posttransplant Considerationsmentioning

confidence: 99%

“…The authors concluded that, compared with warfarin, DOACs are well tolerated and effective at preventing and managing thromboembolic events among renal transplant recipients. 85…”

Section: Posttransplant Considerationsmentioning

confidence: 99%

“…The authors concluded that calcineurin inhibitors had no major impact on the exposure of the DOACs and that these anticoagulants appear to be safe and effective in the renal transplant population. 84 In a recent retrospective, single-center analysis by Zaitoun et al, 85 8 renal transplant recipients maintained on a DOAC were compared with matched patients receiving warfarin (n = 8). There were no thromboembolic events or bleeding events in patients treated with a DOAC, whereas there were no thromboembolic events but 3 episodes of bleeding in the warfarin-treated patients.…”

Section: Kidney Transplantmentioning

confidence: 99%

See 1 more Smart Citation

A Review of Direct-acting Oral Anticoagulants and Their Use in Solid Organ Transplantation

et al. 2022

View full text Add to dashboard Cite

Direct-acting oral anticoagulant (DOAC) use has increased dramatically since their introduction because of the growing evidence of proven efficacy and enhanced safety compared with warfarin and the low-molecular-weight heparins in the general population. Unfortunately, there is a dearth of quality data regarding the safety and efficacy of the DOACs in patients awaiting organ transplant and those who received a solid organ transplant. This review aims to evaluate the available literature and considerations regarding anticoagulation use in transplant recipients, focusing on preoperative, perioperative, and postoperative DOAC use.

show abstract

Warfarin

2022

Reactions Weekly

View full text Add to dashboard Cite

The Use of Non–Vitamin K Antagonist Oral Anticoagulants in Post-Kidney Transplantation, Single-Center Experience

Cited by 3 publications

References 18 publications

Safety of Non-Vitamin K Antagonist Oral Anticoagulant Treatment in Patients with Chronic Kidney Disease and Kidney Transplant Recipients

Safety of Non-Vitamin K Antagonist Oral Anticoagulant Treatment in Patients with Chronic Kidney Disease and Kidney Transplant Recipients

A Review of Direct-acting Oral Anticoagulants and Their Use in Solid Organ Transplantation

Warfarin

Contact Info

Product

Resources

About